Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease
- 1 July 2017
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (7), 1271-1277
- https://doi.org/10.1373/clinchem.2016.269027
Abstract
BACKGROUND: Deficiency of the lysosomal enzyme acid α-glucosidase (GAA) causes Pompe disease. Newborn screening for Pompe disease is ongoing, and improved methods for distinguishing affected patients from those with pseudodeficiency, especially in the Asian population, would substantially reduce the number of patient referrals for clinical follow-up. METHODS: We measured the enzymatic activity of GAA in dried blood spots on newborn screening cards (DBS) using a tandem mass spectrometry (MS/MS) assay. The assay displayed a relatively large analytical range compared to the fluorimetric assay with 4-methylumbelliferyl-α-glucoside. DBS from newborns confirmed to have infantile-onset Pompe disease (IOPD, n = 11) or late-onset Pompe disease (LOPD) (n = 12) and those from patients bearing pseudodeficiency alleles with or without Pompe mutations, or Pompe disease carriers (n = 230) were studied. RESULTS: With use of the MS/MS GAA assay in DBS, 96% of the pseudodeficiency newborns and all of the Pompe disease carriers were well separated from the IOPD and LOPD newborns. The fluorimetric assay separated <10% of the pseudodeficiencies from the IOPD/LOPD group. CONCLUSIONS: The relatively large analytical range MS/MS GAA assay but not the fluorimetric assay in DBS provides a robust approach to reduce the number of referrals and should dramatically facilitate newborn screening of Pompe disease.Keywords
Funding Information
- National Institutes of Health
This publication has 12 references indexed in Scilit:
- Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass SpectrometryMolecular Genetics and Metabolism, 2016
- Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better OutcomesThe Journal of Pediatrics, 2015
- Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass SpectrometryThe Journal of Pediatrics, 2013
- Algorithm for Pompe disease newborn screening: Results from the Taiwan screening programMolecular Genetics and Metabolism, 2012
- Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometryClinica Chimica Acta; International Journal of Clinical Chemistry, 2010
- Multiplex Enzyme Assay Screening of Dried Blood Spots for Lysosomal Storage Disorders by Using Tandem Mass SpectrometryClinical Chemistry, 2008
- Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening ProgramPublished by American Academy of Pediatrics (AAP) ,2008
- Methods for a prompt and reliable laboratory diagnosis of Pompe disease: Report from an international consensus meetingMolecular Genetics and Metabolism, 2008
- Tandem Mass Spectrometry for the Direct Assay of Enzymes in Dried Blood Spots: Application to Newborn Screening for Krabbe DiseaseClinical Chemistry, 2004
- Molecular genetic study of Pompe disease in Chinese patients in TaiwanHuman Mutation, 1999